Leukemia/MDS Clinical Trials
Category:Adult
Status:Active
Displaying trials 1 - 30 of 48 in total
Double Cord Versus Haploidentical (BMT CTN 1101)
Hematopoietic cell transplants (HCT)are one treatment option for people with leukemia or lymphoma. Family members,unrelated donors or banked umbilical cordblood units with similar tissue type can b...
Diagnosis: Leukemia/MDS, Hodgkin's Lymphoma
Phase: 3
Protocol Number: 12-188
This randomized phase III trial studies combination chemotherapy with blinatumomab to see how well it works compared to induction chemotherapy alone in treating patients with newly diagnosed breakp...
Diagnosis: Leukemia/MDS
Phase: 3
Protocol Number: 15-709
The study investigates the time to engraftment of a mesenchymal expanded cord blood unit in patients with hematologic malignancies undergoing transplantation with myeloablative conditioning.
Diagnosis: Non-Hodgkin's Lymphoma, Leukemia/MDS
Phase: 3
Protocol Number: 14-179
Busulfan/Clofarabine + Allogeneic Stem Cell Transplantation
This research is a phase II clinical trial. Phase II clinical trials test the effectiveness of an investigational intervention to learn whether it works in treating a specific cancer. "Investi...
Diagnosis: Leukemia/MDS
Phase: 2
Protocol Number: 12-128
Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)
The goal of this clinical research study is to compare how 2 different drugs, decitabine and azacitidine, when given on a shorter than standard dosing schedule, may help to control MDS. The safety ...
Diagnosis: Leukemia/MDS
Phase: 2
Protocol Number: 15-180
We propose a multi-institutional phase II haplo-identical T cell replete BMT study in children with high-risk leukemias. The myeloablative conditioning regimen prescribed will be TBI-based for lymp...
Diagnosis: Leukemia/MDS
Phase: 2
Protocol Number: 16-605
Pyrimethamine for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
In this research study we will start by looking for the highest dose of pyrimethamine that can be given safely to CLL patients without severe or unmanageable side effects. This dose will then be us...
Diagnosis: Leukemia/MDS
Phase: 1 / 2
Protocol Number: 09-421
This 2-stage, open-label study will evaluate safety and pharmacokinetics of ASTX727, as well as determine the dose for the study's second stage. In the second stage the selected dose will be co...
Diagnosis: Leukemia/MDS
Phase: 1 / 2
Protocol Number: 14-195
This research study is studying a targeted therapy known as GO-203-2C as a possible treatment for with acute myeloid leukemia (AML) both alone and in combination with decitabine. GO-203-2c targets ...
Diagnosis: Leukemia/MDS
Phase: 1 / 2
Protocol Number: 14-222
SL-401 in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia
This is a non-randomized, open-label, multi center study. A cycle of therapy is 5 consecutive days every 21 days for 6 or more cycles. Stage I will consist of a brief run-in period in which patient...
Diagnosis: Leukemia/MDS
Phase: 1 / 2
Protocol Number: 14-454
A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib
The purpose of this study is to find out if treating Chronic Myelomonocytic Leukemia (CMML) with a study drug [ruxolitinib] can improve outcomes of patients with CMML. The first step of the study i...
Diagnosis: Leukemia/MDS
Phase: 1 / 2
Protocol Number: 14-384
This is a non-randomized open label multi-center study. Patients who are in their first complete remission (CR) following induction therapy will be treated with SL-401, which will be administered a...
Diagnosis: Leukemia/MDS
Phase: 1 / 2
Protocol Number: 15-456
This Phase 1b/2 study is an open-label, randomized, multicenter trial to evaluate the safety and efficacy of oral AG-120 + SC azacitidine and oral A-221 + Subcutaneous (SC) azacitidine in subjects ...
Diagnosis: Leukemia/MDS
Phase: 1 / 2
Protocol Number: 16-057
This is a non-randomized open label multi-center study. Patients with high-risk myeloproliferative neoplasms (systemic mastocytosis [SM], advanced symptomatic hypereosinoophic disorder [PED], myelo...
Diagnosis: Leukemia/MDS
Phase: 1 / 2
Protocol Number: 16-149
Brentuximab Vedotin + Chemo for AML
This research study is a Phase I clinical trial. Phase I trials test the safety of an investigational drug or combination of drugs. These trials also try to define the appropriate dose of the inves...
Diagnosis: Leukemia/MDS
Phase: 1
Protocol Number: 13-040
A Phase I Study of Oral ABL001 in Patients With CML or Ph+ ALL
The design of a phase I, open label, dose finding study was chosen in order to establish a safe and tolerated dose of single agent ABL001 in CML and Ph+ ALL patients who are relapsed or refractory ...
Diagnosis: Leukemia/MDS
Phase: 1
Protocol Number: 14-117
This research study is evaluating a combination of drugs considered standard treatment for children and young adults with acute lymphoblastic leukemia (ALL), in combination with a new drug called M...
Diagnosis: Leukemia/MDS
Phase: 1
Protocol Number: 14-200
This research study is evaluating drugs called bortezomib and lenalidomide as a possible treatment for myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The purpose of this research s...
Diagnosis: Leukemia/MDS
Phase: 1
Protocol Number: 14-213
TEN-010 is a small molecule, bromodomain and extra-terminal domain (BET) bromodomain inhibitor. This study is designed to characterize the safety, tolerability, and pharmacokinetics of TEN-010 in p...
Diagnosis: Leukemia/MDS
Phase: 1
Protocol Number: 14-505
This research study is evaluating a combination of two drugs, ibrutinib and obinutuzumab, as a possible treatment for Chronic Lymphocytic Leukemia (CLL).
Diagnosis: Leukemia/MDS
Phase: 1
Protocol Number: 15-283
To determine and evaluate a safe and tolerated dose of HDM201 in adult patients with selected advanced tumors characterized by wild-type TP53.
Diagnosis: Leukemia/MDS
Phase: 1
Protocol Number: 15-289
MLN 9708 in Induction and Consolidation for Adults With AML >= 60 Years of Age
This research study is evaluating drugs called Millennium 9708 (referred to as MLN9708) in combination with standard therapy for acute myeloid leukemia (AML) consisting of daunorubicin and cytarabi...
Diagnosis: Leukemia/MDS
Phase: 1
Protocol Number: 15-276
This is an open label, multicenter Phase 1 study to determine the MTD, dosing schedule and RP2D of IMGN779 when administered as mono-therapy to adult AML patients with CD33 -positive disease.
Diagnosis: Leukemia/MDS
Phase: 1
Protocol Number: 16-215
A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
CC-90009-AML-001 is a phase 1, open-label, dose escalation and expansion, study in subjects with relapsed or refractory acute myeloid leukemia
Diagnosis: Leukemia/MDS
Phase: 1
Protocol Number: 16-426
This study will find the highest acceptable treatment dose of cord blood, culture expanded natural killer (NK) cells, a kind of immune cell, in patients with relapsed and/or refractory acute myeloi...
Diagnosis: Leukemia/MDS
Phase: 1
Protocol Number: 16-373
This phase I trial studies the side effects and best dose of ipilimumab when given together with decitabine in treating patients with myelodysplastic syndrome or acute myeloid leukemia that has ret...
Diagnosis: Leukemia/MDS
Phase: 1
Protocol Number: 17-718
This is a Phase 1b, open-label, non-randomized, multicenter study to evaluate the safety of orally administered ABT-199 combined with decitabine or azacitidine and the preliminary efficacy of these...
Diagnosis: Leukemia/MDS
Phase:
Protocol Number: 14-353
This is a Phase 1, open-label, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antineoplastic activity of BLU-285, administered...
Diagnosis: Leukemia/MDS
Phase:
Protocol Number: 15-559
Study of INCB053914 in Subjects With Advanced Malignancies
This is an open-label, dose-escalation study of the PIM kinase inhibitor INCB053914 in subjects with advanced malignancies. The study will be conducted in 2 parts. Part 1 (dose escalation) will eva...
Diagnosis: Leukemia/MDS
Phase:
Protocol Number: 15-576
This two-stage study is designed to investigate the antitumor activity of tipifarnib in approximately 58 eligible subjects with very low, low or INT risk MDS who have no known curative treatment. E...
Diagnosis: Leukemia/MDS
Phase:
Protocol Number: 16-181
